Chemotherapy-Induced Neutropenia (CIN) Therapeutics -Pipeline Assessment and Market Forecasts to 2018

Oct 26, 2011, 05:31 ET from Reportlinker

NEW YORK, Oct. 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Chemotherapy-Induced Neutropenia (CIN) Therapeutics –Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0661217/Chemotherapy-Induced-Neutropenia-CIN-Therapeutics-–Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

Chemotherapy-Induced Neutropenia (CIN) Therapeutics –Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Chemotherapy-Induced Neutropenia (CIN) Therapeutics –Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global CIN therapeutics market. The report identifies the key trends shaping and driving the global CIN therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CIN sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global Chemotherapy-induced Neutropenia (CIN) therapeutics market was valued at $3.6 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 5.8% to reach $4.8 billion in 2010. The market is forecast to grow at a CAGR of 2.3% over the next eight years to reach $5.8 billion by 2018. This decline in growth rate is primarily attributed to the expected patent expiry of Neupogen in 2013 (2006 in Europe) and Neulasta in 2015 which will make way for the entry of biosimilars (generic version of biologics) into the market. The increase in prescription population will help in partially offsetting the revenue loss due to the patent expiries.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the CIN market. Its scope includes -

- Analysis of seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan), with CIN market revenues data from 2005 to 2010, and forecasts to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as long acting recombinant PEGylated G-CSFs, long-acting recombinant human albumin-G-CSFs, long acting glyco-PEGylated recombinant human G-CSFs, long-acting recombinant GM-CSFs, allogeneic cell-based therapies, recombinant fusion protein G-CSFs, neutrophil stimulators, recombinant protease inhibitors and hematopoeitic stem cell stimulators.

- Analysis of the current and future competition in the global CIN therapeutics market. Key market players covered are Eurofarma Laboratorios Ltda, Green Cross Corporation in collaboration with Symyoo, Intas Biopharmaceuticals Ltd. in collaboration with Apotex Inc. and Teva Pharmaceuticals.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the CIN therapeutics market.

- Analysis of key recent licensing and partnership agreements in CIN therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global CIN market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global CIN therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global CIN therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Executive Summary 8

2.1 The CIN Therapeutics Market is Forecast to Show Slow Growth Until 2018 8

2.2 The CIN Therapeutics Market has Significant Unmet Need in Terms of Cost-Effectiveness 9

2.3 CIN Developmental Pipeline Lacks Novelty and is Crowded with Biosimilars 10

2.4 Entry of Biosimilars in the CIN Therapeutics Market 11

3 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Introduction 12

3.1 Overview 12

3.1.1 Classification of CIN 16

3.1.2 Febrile Neutropenia 17

3.2 Epidemiology 17

3.3 Symptoms 17

3.4 Etiology 18

3.5 Pathophysiology 18

3.6 Risk factors for CIN 19

3.7 Diagnosis 23

3.8 Treatment of CIN 24

3.9 GlobalData Pipeline Report Guidance 31

4 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Market Characterization 32

4.1 CIN Therapeutics Market Size (2005-2010) – Global 32

4.2 CIN Therapeutics Market Forecast (2010-2018) – Global 34

4.3 CIN Therapeutics Market Size (2005-2010) – The US 36

4.4 CIN Therapeutics Market Forecast (2010-2018) – The US 37

4.5 CIN Therapeutics Market Size (2005-2010) – France 38

4.6 CIN Therapeutics Market Forecast (2010-2018) – France 41

4.7 CIN Therapeutics Market Size (2005-2010) – Germany 43

4.8 CIN Therapeutics Market Forecast (2010-2018) – Germany 45

4.9 CIN Therapeutics Market Size (2005-2010) – Italy 47

4.10 CIN Therapeutics Market Forecast (2010-2018) – Italy 49

4.11 CIN Therapeutics Market Size (2005-2010) – Spain 51

4.12 CIN Therapeutics Market Forecast (2010-2018) – Spain 53

4.13 CIN Therapeutics Market Size (2005-2010) – The UK 55

4.14 CIN Therapeutics Market Forecast (2010-2018) – The UK 57

4.15 CIN Therapeutics Market Size (2005-2010) – Japan 59

4.16 CIN Therapeutics Market Forecast (2010-2018) – Japan 60

4.17 Drivers and Barriers for the CIN Therapeutics Market 62

4.17.1 Drivers for the CIN Therapeutics Market 62

4.17.2 Barriers for the CIN Therapeutics Market 63

4.18 Key Events Impacting the Future Market 64

4.19 Opportunity and Unmet Need Analysis 64

4.19.1 Key Takeaway 66

5 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Competitive Assessment 68

5.1 Overview 68

5.2 Strategic Competitor Assessment 68

5.2 Product Profile for the Major Marketed Products in the CIN Therapeutics Market 70

5.2.1 Neulasta (pegfilgrastim) 70

5.2.2 Neupogen (filgrastim) 71

5.2.3 Leukine (sargramostim) 72

5.2.4 Granocyte/ Neutrogin (lenograstim) 73

5.3 Key Takeaway 75

6 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Pipeline Assessment 76

6.1 Overview 76

6.2 Strategic Pipeline Assessment 76

6.2.1 CIN Therapeutics – Pre-registration Pipeline 77

6.2.2 CIN Therapeutics – Phase III Pipeline 77

6.2.3 CIN Therapeutics – Phase II Pipeline 78

6.2.4 CIN Therapeutics – Phase I/II Pipeline 78

6.2.5 CIN Therapeutics – Phase I Pipeline 78

6.2.6 CIN Therapeutics – Preclinical Pipeline 78

6.3 CIN Therapeutics – Pipeline by Mechanism of Action 79

6.4 CIN Technology Trends Analytical Framework 80

6.5 Molecule Profile for Promising Drugs under Clinical Development 81

6.5.1 Neugranin 81

6.5.2 Lipegfilgrastim (XM22) 82

6.5.3 Filgrastim 82

6.5.4 Neukine 82

6.5.5 GCPGC 83

6.6 Key takeaway 83

7 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Clinical Trials Mapping 84

7.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 84

7.2 Clinical Trials by Phase 85

7.3 Clinical Trials by Status 86

7.4 Overall Sponsors 86

7.5 Prominent Sponsors 87

7.6 Participants in Therapeutic Clinical Trials – Companies 88

8 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Strategic Assessment 90

8.1 CIN Therapeutics: Implications for Future Market Competition 90

9 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Future Players 93

9.1 Introduction 93

9.2 Company Profiles 93

9.2.1 Teva Pharmaceutical Industries Limited 93

9.2.2 Eurofarma Laboratorios Ltda. 95

9.2.3 Green Cross Corporation 96

9.2.4 Intas Biopharmaceuticals Ltd. 96

9.2.5 Apotex Inc. 97

10 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Appendix 99

10.1 Definitions 99

10.2 Acronyms 99

10.3 Research Methodology 100

10.3.1 Coverage 101

10.3.2 Secondary Research 101

10.3.3 Forecasting 101

10.3.4 Primary Research 104

10.3.5 Expert Panel Validation 105

10.4 Contact Us 105

10.5 Disclaimer 105

10.6 Bibliography 106

List of Tables

Table 1: CIN Therapeutics Market, Global, Forecast ($m), 2005–2010 34

Table 2: CIN Therapeutics Market, Global, Forecast ($m), 2010–2018 36

Table 3: CIN Therapeutics Market, The US, Revenue ($m), 2005–2010 38

Table 4: CIN Therapeutics Market, The US, Forecast ($m), 2010–2018 39

Table 5: CIN Therapeutics Market, France, Revenue ($m), 2005–2010 41

Table 6: CIN Therapeutics Market, France, Forecast ($m), 2010–2018 43

Table 7: CIN Therapeutics Market, Germany, Revenue ($m), 2005–2010 45

Table 8: CIN Therapeutics Market, Germany, Forecast ($m), 2010–2018 47

Table 9: CIN Therapeutics Market, Italy, Revenue ($m), 2005–2010 49

Table 10: CIN Therapeutics Market, Italy, Forecast ($m), 2010–2018 51

Table 11: CIN Therapeutics Market, Spain, Revenue ($m), 2005–2010 53

Table 12: CIN Therapeutics Market, Spain, Forecast ($m), 2010–2018 55

Table 13: CIN Therapeutics Market, The UK, Revenue ($m), 2005–2010 57

Table 14: CIN Therapeutics Market, The UK, Forecast ($m), 2010–2018 59

Table 15: CIN Therapeutics Market, Japan, Revenue ($m), 2005–2010 60

Table 16: CIN Therapeutics Market, Japan, Forecast ($m), 2010–2018 62

Table 17: CIN Market, Global, Major Marketed Products Comparison, 2011 75

Table 18: CIN Therapeutics – Pre-registration Pipeline, 2011 78

Table 19: CIN Therapeutics – Phase III Pipeline, 2011 78

Table 20: CIN Therapeutics – Phase II Pipeline, 2011 79

Table 21: CIN Therapeutics – Phase I/II Pipeline, 2011 79

Table 22: CIN Therapeutics – Phase I Pipeline, 2011 79

Table 23: CIN Therapeutics – Preclinical Pipeline, 2011 79

Table 24: CIN Therapeutics – Clinical Trials by Country, 2011 85

Table 25: CIN Therapeutics – Clinical Trials by Phase, 2011 86

Table 26: CIN Therapeutics – Clinical Trials by Status (%), 2011 87

Table 27: CIN Therapeutics – Overall Sponsors (%), 2011 88

Table 28: CIN Therapeutics – Prominent Sponsors, 2011 89

Table 29: CIN Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 90

Table 30: Teva Pharmaceuticals- Hematological Disorders Pipeline, 2011 95

Table 31: Teva Pharmaceuticals- CIN Pipeline, 2011 96

Table 32: Eurofarma Laboratorios Ltda., CIN Pipeline, 2011 96

Table 33: Green Cross Corporation, Hematological Disorders Pipeline, 2011 97

Table 34: Green Cross Corporation, CIN Pipeline, 2011 97

Table 35: Intas Biopharmaceuticals Ltd., CIN Pipeline, 2011 98

Table 36: Apotex Inc., CIN Pipeline, 2011 99

List of Figures

Figure 1: CIN Therapeutics Market, Global, Revenue and Forecasts ($bn), 2005–2018 9

Figure 2: CIN Therapeutics, Opportunity and Unmet Need, 2011 10

Figure 3: CIN Therapeutics, Hematopoesis – Formation and Development of Blood Cells 13

Figure 4: CIN Therapeutics, Risk of Neutropenic Complications in the First Cycle of Chemotherapy 14

Figure 5: CIN Therapeutics, The Course of Neutropenic Complications 15

Figure 6: CIN Therapeutics, CIN Grading by National Cancer Institute 16

Figure 7: CIN Therapeutics, Risk of Neutropenic Complications in the First Cycle of Chemotherapy by Tumor Type 20

Figure 8: CIN Therapeutics, Chemotherapy Regimens with a High (>20%) Febrile Neutropenia Risk 22

Figure 9: CIN Therapeutics, Bone Marrow Aspiration and Biopsy 23

Figure 10: CIN Therapeutics, Marketed Drugs 26

Figure 11: CIN Therapeutics, Risks and Benefits of CSF Use 27

Figure 12: CIN Therapeutics, Alignment of Recommendations for the Prophylactic Use of G-CSFs 29

Figure 13: CIN Therapeutics, NCCN – Decision Tree for Primary Prophylaxis 30

Figure 14: CIN Therapeutics, NCCN Guidelines for Treatment 31

Figure 15: CIN Therapeutics Market, Global, Revenue ($m), 2005–2010 33

Figure 16: CIN Therapeutics Market, Global, Forecast ($m), 2010–2018 36

Figure 17: CIN Therapeutics Market, the US, Revenue ($m), 2005–2010 37

Figure 18: CIN Therapeutics Market, The US, Forecast ($m), 2010–2018 38

Figure 19: CIN Therapeutics Market, France, Revenue ($m), 2005–2010 40

Figure 20: CIN Therapeutics Market, France, Forecast ($m), 2010–2018 42

Figure 21: CIN Therapeutics Market, Germany, Revenue ($m), 2005–2010 44

Figure 22: CIN Therapeutics Market, Germany, Forecast ($m), 2010–2018 46

Figure 23: CIN Therapeutics Market, Italy, Revenue ($m), 2005–2010 48

Figure 24: CIN Therapeutics Market, Italy, Forecast ($m), 2010–2018 51

Figure 25: CIN Therapeutics Market, Spain, Revenue ($m), 2005–2010 52

Figure 26: CIN Therapeutics Market, Spain, Forecast ($m), 2010–2018 54

Figure 27: CIN Therapeutics Market, The UK, Revenue ($m), 2005–2010 56

Figure 28: CIN Therapeutics Market, The UK, Forecast ($m), 2010–2018 58

Figure 29: CIN Therapeutics Market, Japan, Revenue ($m), 2005–2010 60

Figure 30: CIN Therapeutics Market, Japan, Forecast ($m), 2010–2018 62

Figure 31: CIN Therapeutics Market, Drivers and Restraints, 2011 65

Figure 32: CIN Therapeutics, Opportunity and Unmet Need, 2011 66

Figure 33: CIN Therapeutics – Strategic Competitor Assessment, 2011 69

Figure 34: CIN Therapeutics – Pipeline by Phase of Clinical Development, 2011 78

Figure 35: CIN Therapeutics – Clinical Pipeline by Mechanism Of Action, 2011 80

Figure 36: CIN Therapeutics, Technology Trends Analytical Framework, , 2011 81

Figure 37: CIN Therapeutics, Technology Trends Analytical Framework, Description, 2011 82

Figure 38: CIN Therapeutics – Clinical Trials by Country, 2011 85

Figure 39: CIN Therapeutics – Clinical Trials by Phase (%), 2011 86

Figure 40: CIN Therapeutics – Clinical Trials by Status (%), 2011 87

Figure 41: CIN Therapeutics – Overall Sponsors (%), 2011 88

Figure 42: CIN Therapeutics – Prominent Sponsors (%), 2011 89

Figure 43: CIN Therapeutics Market, Implications for Future Market Competition, 2011 91

Figure 44: CIN Therapeutics – Pipeline by Company, 2011 93

Figure 45: GlobalData Market Forecasting Model 104Teva Pharmaceutical Industries Limited

Eurofarma Laboratorios Ltda.

Green Cross Corporation

Intas Biopharmaceuticals Ltd.

Apotex Inc.

To order this report:

General Medicine and Specialty Medicine Industry: Chemotherapy-Induced Neutropenia (CIN) Therapeutics –Pipeline Assessment and Market Forecasts to 2018

General Medicine and Specialty Medicine Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com